Skip to main content

Elanco Animal Health Incorporat (ELAN) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Momentum 2.5/10 is below the 5.0 floor at $22.05 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Earnings in 6 days (event risk).

Elanco Animal Health is a global animal health company selling ~200 branded products for pet health (parasiticides, dermatology, vaccines) and farm animals (antibiotics, productivity enhancers) in 90+ countries, with the U.S. accounting for 47% of 2025 total revenue. Revenue is... Read more

Stop $20.97Target $24.86(analyst − 13%)A.R:R 1.8:1
Analyst target$28.57+29.6%14 analysts
$24.86our TP
$22.05price
$28.57mean
$20
$32

Sell if holding. Momentum 2.5/10 is below the 5.0 floor at $22.05 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Earnings in 6 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.2/10, moderate confidence.

Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.

Thesis

Rewards
Strong earnings beat streak (4/4)
Risks
Earnings in 6 days (event risk)
Negative momentum

Key Metrics

P/E (TTM)
P/E (Fwd)18.7
Mkt Cap$10.9B
EV/EBITDA16.2
Profit Mgn-4.9%
ROE-3.7%
Rev Growth12.2%
Beta1.88
DividendNone
Rating analysts22

Quality Signals

Piotroski F9/9

Options Flow

P/C0.81neutral
IV73%elevated
Max Pain$16-27.4% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMProducttop five products and/or product families38%
    10-K Item 1A: 'Our top five products and/or product families, Advantage Family, Seresto, Credelio Family, Rumensin and Maxiban / Monteban represented approximately 38% of our total revenue in 2025'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Macd
1.9
Ma Position
4.0
Rsi
5.5
Volume distribution (falling OBV)Above 200-day MA

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.8
Value Rank
5.7
Growth Rank
5.9
GatesMomentum 2.5<4.5EARNINGS PROXIMITY 6d<=7dA.R:R 1.8 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARSuitability: Aggressive
RSI
40 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $21.62Resistance $24.43

Price Targets

$21
$25
A.Upside+12.7%
A.R:R1.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Momentum score 2.5/10 — below 4.5 minimum
! EARNINGS_PROXIMITY:6d<=7d

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ELAN stock a buy right now?

Sell if holding. Momentum 2.5/10 is below the 5.0 floor at $22.05 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Earnings in 6 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $20.97. Score 5.2/10, moderate confidence.

What is the ELAN stock price target?

Take-profit target: $24.86 (+12.8% upside). Prior stop was $20.97. Stop-loss: $20.97.

What are the risks of investing in ELAN?

Earnings in 6 days (event risk); Negative momentum.

Is ELAN overvalued or undervalued?

Elanco Animal Health Incorporat trades at a P/E of N/A (forward 18.7). TrendMatrix value score: 5.4/10. Verdict: Sell.

What do analysts say about ELAN?

22 analysts cover ELAN with a consensus score of 4.3/5. Average price target: $29.

What does Elanco Animal Health Incorporat do?Elanco Animal Health is a global animal health company selling ~200 branded products for pet health (parasiticides,...

Elanco Animal Health is a global animal health company selling ~200 branded products for pet health (parasiticides, dermatology, vaccines) and farm animals (antibiotics, productivity enhancers) in 90+ countries, with the U.S. accounting for 47% of 2025 total revenue. Revenue is earned through distributors, veterinarians, and direct sales to farm animal producers across multiple species.

Related stocks: NBIX (Neurocrine Biosciences, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · BCRX (BioCryst Pharmaceuticals, Inc.) · COLL (Collegium Pharmaceutical, Inc.) · ANIP (ANI Pharmaceuticals, Inc.)